Molecular structure of SB 225002, CAS Number: 182498-32-4
SB 225002 (CAS 182498-32-4)
See product citations (2)
Alternate Names:
N-(2-Bromophenyl)-N′-(2-hydroxy-4-nitrophenyl)urea; 1-(2-bromophenyl)-3-(2-hydroxy-4-nitrophenyl)urea
Application:
SB 225002 is a selective antagonist of CXCR2
CAS Number:
182498-32-4
Purity:
>98%
Molecular Weight:
352.14
Molecular Formula:
C13H10BrN3O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
SB 225002 is a selective non-peptide CXCR2 inhibitor which suppresses IL-8 induced neutrophil chemotaxis and margination. In addition, SB 225002 reduces MPO activity, IL-1beta, MIP-2, and keratinocyte-derived chemokine (KC) levels. Further studies suggest that SB 225002 decreases the expression of vascular endothelial growth factor, inducible NOS (NO synthase), and Cox-2 (cyclooxygenase-2 proteins) in colon tissue.
SB 225002 (CAS 182498-32-4) References
- The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice. | Bento, AF., et al. 2008. J Leukoc Biol. 84: 1213-21. PMID: 18653784
- The effects of the selective and non-peptide CXCR2 receptor antagonist SB225002 on acute and long-lasting models of nociception in mice. | Manjavachi, MN., et al. 2010. Eur J Pain. 14: 23-31. PMID: 19264522
- SB225002 promotes mitotic catastrophe in chemo-sensitive and -resistant ovarian cancer cells independent of p53 status in vitro. | Du, M., et al. 2013. PLoS One. 8: e54572. PMID: 23359652
- SB225002 Induces Cell Death and Cell Cycle Arrest in Acute Lymphoblastic Leukemia Cells through the Activation of GLIPR1. | de Vasconcellos, JF., et al. 2015. PLoS One. 10: e0134783. PMID: 26302043
- Therapeutic inhibition of CXC chemokine receptor 2 by SB225002 attenuates LPS-induced acute lung injury in mice. | Cao, Q., et al. 2018. Arch Med Sci. 14: 635-644. PMID: 29765453
- SB225002 inhibits prostate cancer invasion and attenuates the expression of BSP, OPN and MMP‑2. | Xu, M., et al. 2018. Oncol Rep. 40: 726-736. PMID: 29917166
- CXCL5/CXCR2 modulates inflammation-mediated neural repair after optic nerve injury. | Liu, YF., et al. 2021. Exp Neurol. 341: 113711. PMID: 33785307
- Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin. | Cheng, Y., et al. 2021. Mol Cancer. 20: 62. PMID: 33814009
- Molecular insights into the microtubules depolymerizing activity of the IL-8 receptor B antagonist SB225002. | Goda, AE. and Sakai, T. 2022. Eur Rev Med Pharmacol Sci. 26: 3726-3734. PMID: 35647855
- Combining TMZ and SB225002 induces changes of CXCR2 and VEGFR signalling in primary human endothelial cells in vitro. | Urbantat, RM., et al. 2022. Oncol Rep. 48: PMID: 35856448
- CXCL1-CXCR2 signalling mediates hypertensive retinopathy by inducing macrophage infiltration. | Wang, S., et al. 2022. Redox Biol. 56: 102438. PMID: 35981418
- Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade. | Conche, C., et al. 2023. Gut.. PMID: 36707233
- Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. | White, JR., et al. 1998. J Biol Chem. 273: 10095-8. PMID: 9553055
Inhibitor of:
β-defensin 46, ANP32D, C230078M08Rik, CA X, CCL (C-C motif chemokine ligand), CCL27b, CCRL2, CCXCKR, CKR-1, CKR-6, CXCL13, CXCL16, EG665186, eoxtaxin-3, fractalkine, Granulocytes, GROα, GRO1, HCC-4, IL-8, IL-8RB, Integrin βId, MIP-2α, OTTMUSG00000006698, OTTMUSG00000010747, PAF Acetylhydrolase, RANTES, and RFRP-1.Activator of:
T Neutrophil, VCC-1, and XCR1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SB 225002, 1 mg | sc-202803 | 1 mg | $36.00 | |||
SB 225002, 5 mg | sc-202803A | 5 mg | $102.00 |